SCHEMBL25015126

SCHEMBL25015126

COC(=O)c1nc(-c2ccc3c(n2)C(=O)C(N)=C(OC)C3=O)c(N)c(-c2ccc(OC)c(OC)c2O)c1C

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.87
▸ LMNA P02545 3/20 0.87
▸ SMN1; SMN2 Q16637 3/20 0.87
▸ KDM4E B2RXH2 3/20 0.87
▸ NPC1 O15118 3/20 0.87
▸ RAB9A P51151 3/20 0.87
▸ POLB P06746 2/20 0.87
▸ MAPK1 P28482 2/20 0.87
▸ MEN1 O00255 2/20 0.87
▸ KMT2A Q03164 2/20 0.87
▸ TGM2 P21980 1/20 0.87
▸ PDE4A P27815 1/20 0.87
▸ GALK1 P51570 1/20 0.87
▸ BLM P54132 1/20 0.87
▸ PDE4B Q07343 1/20 0.87
▸ PDE4C Q08493 1/20 0.87
▸ PDE4D Q08499 1/20 0.87
▸ EP300 Q09472 1/20 0.87
▸ ATM Q13315 1/20 0.87
▸ HIF1A Q16665 1/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30260509 1.00 MAPT (0.87) MAPTLMNASMN1; SMN2KDM4ENPC1
Streptonigrin SCHEMBL29371276 0.93 MAPT (1.00) MAPTLMNASMN1; SMN2KDM4ENPC1
Streptonigrin SCHEMBL29821157 0.93 MAPT (1.00) MAPTLMNASMN1; SMN2KDM4ENPC1
Streptonigrin SCHEMBL29374011 0.93 MAPT (1.00) MAPTLMNASMN1; SMN2KDM4ENPC1
SCHEMBL20257205 0.93 SMN1; SMN2 (0.75) MAPTLMNASMN1; SMN2KDM4ENPC1
SCHEMBL23484180 0.89 FNTA (0.70) MAPTLMNASMN1; SMN2KDM4ENPC1
Streptonigrin SCHEMBL23421492 0.85 LMNA (0.85) MAPTLMNASMN1; SMN2KDM4ENPC1
SCHEMBL20250622 0.85 FNTA (0.65) MAPTLMNASMN1; SMN2KDM4ENPC1
Streptonigrin SCHEMBL6299739 0.85 LMNA (0.84) MAPTLMNASMN1; SMN2KDM4ENPC1
SCHEMBL29885591 0.82 LMNA (0.70) MAPTLMNASMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER THE TRUSTEES OF DARTMOUTH COLLEGE 2023-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER MYCBP, MYC, TERF2IP MAPT 3232/4885LMNA 2253/4885SMN1; SMN2 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback